A Randomized Three-Arm Neoadjuvant and Adjuvant Feasibility and Toxicity Study of a GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine Administered Either Alone or in Combination With Either a Single Intravenous Dose or Daily Metronomic Oral Doses of Cyclophosphamide for the Treatment of Patients With Surgically Resected Adenocarcinoma of the Pancreas.

Trial Profile

A Randomized Three-Arm Neoadjuvant and Adjuvant Feasibility and Toxicity Study of a GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine Administered Either Alone or in Combination With Either a Single Intravenous Dose or Daily Metronomic Oral Doses of Cyclophosphamide for the Treatment of Patients With Surgically Resected Adenocarcinoma of the Pancreas.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; Cyclophosphamide (Primary) ; Tumour cell vaccine-GVAX (Primary) ; Capecitabine; Fluorouracil; Gemcitabine
  • Indications Adenocarcinoma; Head and neck cancer; Pancreatic cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 11 Jan 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
    • 11 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 08 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top